Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
5.53
+0.04 (0.73%)
At close: Apr 28, 2026, 4:00 PM EDT
5.62
+0.09 (1.62%)
After-hours: Apr 28, 2026, 7:23 PM EDT
Valneva SE Employees
Valneva SE had 674 employees as of December 31, 2025. The number of employees decreased by 39 or -5.47% compared to the previous year.
Employees
674
Change (1Y)
-39
Growth (1Y)
-5.47%
Revenue / Employee
$304,260
Profits / Employee
-$200,667
Market Cap
491.15M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| REGENXBIO | 371 |
| 4D Molecular Therapeutics | 196 |
| Entrada Therapeutics | 152 |
| Aura Biosciences | 113 |
| Prelude Therapeutics | 79 |
| Larimar Therapeutics | 71 |
| Armata Pharmaceuticals | 60 |
VALN News
- 3 hours ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - GlobeNewsWire
- 7 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewsWire
- 12 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 25 days ago - Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewsWire
- 4 weeks ago - Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC - GlobeNewsWire
- 5 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewsWire
- 5 weeks ago - Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges - GuruFocus
- 5 weeks ago - An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive - WSJ